Cargando…

Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy

PURPOSE: The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are inflammatory indexes that may reflect immune response to tumors and prognosis. We investigated the prognostic values of pre-treatment and post-treatment NLR and PLR and changes in those ratios in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Yuan, Yuan, Bao-Ying, Hu, Yong, Chen, Gen-Wen, Zhang, Li, Zhao, Xiao-Mei, Chen, Yi-Xing, Zeng, Zhao-Chong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997220/ https://www.ncbi.nlm.nih.gov/pubmed/32099457 http://dx.doi.org/10.2147/CMAR.S231901

Ejemplares similares

Association Between Circulating Lymphocyte Populations and Outcome After Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma
por: Zhuang, Yuan, et al.
Publicado: (2019)

Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma
por: Chen, Yi-Xing, et al.
Publicado: (2020)

Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy
por: Wu, Qi-Qiao, et al.
Publicado: (2022)

Analysis of the factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular carcinoma patients
por: Liu, Xiaojie, et al.
Publicado: (2017)

Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial
por: Chen, Yi-Xing, et al.
Publicado: (2023)

Clinical Values and Markers of Radiation-Induced Liver Disease for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Stereotactic Body Radiotherapy
por: Jia, Jun, et al.
Publicado: (2021)

Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma
por: Que, Jenny, et al.
Publicado: (2016)

Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma
por: Xu, Yingying, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2013)

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Venkat, Puja S., et al.
Publicado: (2017)

Effect of the normal liver mean dose on intrahepatic recurrence in patients with hepatocellular carcinoma after receiving liver stereotactic body radiation therapy
por: Wu, Qi-Qiao, et al.
Publicado: (2022)

Does HCC Etiology Impact the Efficacy of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma? An Asian Liver Radiation Therapy Group Study
por: Kim, Nalee, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy as an Alternative Treatment for Small Hepatocellular Carcinoma
por: Yoon, Sang Min, et al.
Publicado: (2013)

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
por: Schaub, Stephanie K., et al.
Publicado: (2018)

Repeated CyberKnife stereotactic body radiation therapy in hepatocellular carcinoma
por: Sun, Jing, et al.
Publicado: (2020)

Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety
por: Roquette, Isaure, et al.
Publicado: (2022)

The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer stereotactic body radiation therapy: a retrospective study
por: Chen, Meng, et al.
Publicado: (2022)

Screening of Prognostic Biomarkers for Stereotactic Body Radiation Therapy in Primary Liver Cancer
por: Liang, Zhenzhen, et al.
Publicado: (2022)

Frameless stereotactic body radiation therapy for multiple lung metastases
por: Li, Qilin, et al.
Publicado: (2014)

Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery
por: Kim, Mi-Sook, et al.
Publicado: (2015)

Stereotactic body radiation therapy as an effective and safe treatment for small hepatocellular carcinoma
por: Zhang, Tao, et al.
Publicado: (2018)

Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review
por: Gerum, Sabine, et al.
Publicado: (2019)

Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity
por: Lewis, Shirley, et al.
Publicado: (2022)

The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC)
por: Kimura, Tomoki, et al.
Publicado: (2022)

PRELP has prognostic value and regulates cell proliferation and migration in hepatocellular carcinoma
por: Hong, Runqi, et al.
Publicado: (2020)

Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined With Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma
por: Jiang, Changchen, et al.
Publicado: (2021)

CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker
por: Shen, Zhiqing, et al.
Publicado: (2018)

Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma
por: Jun, Baek Gyu, et al.
Publicado: (2018)

Prognostic values of (18)F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy
por: Zhang, Anyu, et al.
Publicado: (2019)

Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm
por: Su, Ting-Shi, et al.
Publicado: (2016)

Stereotactic body radiation therapy using the CyberKnife(®) system for patients with liver metastases
por: Yuan, Zhi-Yong, et al.
Publicado: (2014)

Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma
por: Shen, Ze-Tian, et al.
Publicado: (2017)

SYDE1 Acts as an Oncogene in Glioma and has Diagnostic and Prognostic Values
por: Han, Zhenyuan, et al.
Publicado: (2021)

Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity
por: Liang, Ping, et al.
Publicado: (2016)

Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease
por: Gerum, Sabine, et al.
Publicado: (2018)

Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma
por: Oldrini, Guillaume, et al.
Publicado: (2017)

Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant
por: Wong, Tiffany Cho‐Lam, et al.
Publicado: (2021)

The molecular mechanism of LncRNA34a-mediated regulation of bone metastasis in hepatocellular carcinoma
por: Zhang, Li, et al.
Publicado: (2019)

Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer
por: Xu, Bichun, et al.
Publicado: (2023)

Dosimetric comparison of CT-guided iodine-125 seed stereotactic brachytherapy and stereotactic body radiation therapy in the treatment of NSCLC
por: Li, Ranran, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bjl4da4mre649pj0cdr58kpunb